strong: fixed-dose durvalumab for utc
Published 3 years ago • 21 plays • Length 2:10Download video MP4
Download video MP3
Similar videos
-
1:43
dr. sonpavde discusses a study of fixed-dose durvalumab and tremelimumab in urothelial carcinoma
-
11:11
extending durvalumab maintenance to special populations
-
3:48
poseidon: durvalumab /- tremelimumab chemo in 1l mnsclc
-
1:18
imfinzi® (durvalumab) plus chemotherapy approved in the us as the first immunotherapy regimen...
-
0:43
double immunotherapy with durvalumab and tremelimumab versus quadruple therapy in nsclc
-
12:08
new fda approval: darolutamide for hormone-sensitive disease | mark scholz, md | pcri
-
3:17
topaz-1: the addition of durvalumab to chemotherpay for the treatment of btc in the 1st-line setting
-
2:58
patients reportedly beating cancer with just one tablet a day | 9 news australia
-
2:31
durvalumab plus tremelimumab or durvalumab monotherapy in metastatic urothelial carcinoma
-
6:22
refining which patients benefit from consolidation durvalumab for stage iii unresectable nsclc
-
1:00
trial of durvalumab for bladder cancer
-
2:53
hudson: durvalumab combination therapies to overcome pd-l1 blockade resistance in advanced nsclc
-
1:40
a randomized phase 2 trial of durvalumab with or without sbrt in non-small cell lung cancer
-
2:03
tremelimumab and durvalumab therapy in lung cancer
-
2:12
dutreneo: durvalumab and tremelimumab vs chemo
-
1:03
imfinzi® (durvalumab) plus chemotherapy approved in the us as the first immunotherapy regimen...
-
2:10
poseidon: 4 year follow up of durvalumab and tremelimumab in nsclc
-
3:31
expert comment: caspian trial of durvalumab in sclc | raffaele califano
-
3:39
what is durvalumab’s future as a treatment option in lung cancer?
-
1:06
the mechanism of action of durvalumab in the treatment of urothelial bladder cancer
-
3:19
fda approval of durvalumab for advanced bladder cancer
-
1:49
fda approval of durvalumab for bladder cancer